DS
RIGL icon

DRW Securities’s Rigel Pharmaceuticals RIGL Stock Holding History

DRW Securities’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,804
Closed -$108K – 221
2013
Q4 		$108K Buy
3,804
+304
+9% +$8.92K ﹤0.01% 207
2013
Q3 		$114K Buy
+3,500
New +$128K 0.01% 151

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DRW Securities's RIGL Position: Q1 2014 in Review

DRW Securities sold out of Rigel Pharmaceuticals (RIGL) in Q1 2014, closing a stake of 3,804 shares — an estimated $108K sold.

DRW Securities first reported a position in RIGL in Q3 2013 and held it in 2 quarters. The position peaked at $114K in Q3 2013. 110 funds tracked by Wall St. Rank hold RIGL as of Q1 2014.

  • DRW Securities reported no remaining Rigel Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • DRW Securities sold 3,804 Rigel Pharmaceuticals shares in Q1 2014, an estimated $108K.
  • DRW Securities first reported a position in Rigel Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • DRW Securities's Rigel Pharmaceuticals position peaked at $114K in Q3 2013.
  • 110 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2014.

Based on DRW Securities's 13F filing for Q1 2014, filed 16 May 2014.